الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
Diabetes mellitus and its complications are rapidly becoming the world’s most significant cause of morbidity and mortality (Jang, et al, 2011).
Diabetic retinopathy, the most common microvascular complication of DM, is predicted to be the principal reason of new blindness among working population (Aiello, et al, 2003).
Aim of our study is to verify the reliability of PTX 3 as a marker of DR progression.
We selected 80 subjects with diabetes mellitus their disease duration ranged from 6-22 years.
We divided them into 3 groups according to their fundus examination:
group I: 30 patients with type 2 DM and diabetic retinopathy.
Group2: 30 patients with type 2 DM without diabetic retinopathy.
group 3: 20 control group.
We searched for diabetic retinopathy through fundus examination using direct and indirect ophthalmoscope in addition to fluorescein angiography.
We studied the relation between serum pentraxin 3 levels and diabetic retinopathy in a way to prove that pentraxin 3 associated with development of diabetic retinopathy.
We excluded patients with hypertension, Patients with any form of chronic infection, malignancies, Patients with current or history of receiving any form of immune-modulating drugs, renal impairment, Patients with severe eye disease and retinal detachment and I.V. drug users.
All patients included in this study were subjected to the following:
1. Full history taking (age, gender, duration, smoking, liver disease, hypertension, drugs affect serum lipids).
2. Clinical examination including the following items:
Assessment of anthropometric measures (BMI and waist circumference).
Assessment of blood pressure.
Fundus examination.
3. Routine laboratory investigations including:
Liver function tests.
Blood urea and serum creatinine.
4. Lipid profile including serum triglycerides, high density lipoprotein, low density lipoprotein and total cholesterol level.
5. Serum pentraxin3 levels will be determined by an enzyme linked immunoassay (ELISA) using pentraxin 3 ELISA kits.
6. CRP.
7- Glycosylated hemoglobin (HbA1C).
The following results can be concluded from our thesis:
1. Serum PTX3 level significantly increased in patients with DR more than patients without DR with cut off point 1150pg/ml ,sensitivity 93.3%and specificity 72%
2. Serum CRP level significantly increased in patients with DR more than patients without DR with cut off point of 760pg/ml has sensitivity 93.3% and specificity 68%.
3. Combined use of PTX3 and CRP decrease sensitivity to 76.7%. but combined use increase specificity to 90%.
4. Significant relation between diabetes duration and progression of DR.
5. Significant relation between poor glycemic control and development of DR and its severity.